BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

881 related articles for article (PubMed ID: 17531573)

  • 21. Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions.
    Gulmez O; Yildirir A; Kaynar G; Konas D; Aydinalp A; Ertan C; Ozin B; Muderrisoglu H
    J Thromb Thrombolysis; 2008 Jun; 25(3):239-46. PubMed ID: 17574519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
    Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Mielot C; Bali L; Lambert M; Alessi MC; Bonnet JL
    Thromb Haemost; 2007 Feb; 97(2):282-7. PubMed ID: 17264958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
    Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
    Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.
    Valgimigli M; Campo G; de Cesare N; Meliga E; Vranckx P; Furgieri A; Angiolillo DJ; Sabatè M; Hamon M; Repetto A; Colangelo S; Brugaletta S; Parrinello G; Percoco G; Ferrari R;
    Circulation; 2009 Jun; 119(25):3215-22. PubMed ID: 19528337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of different cardiac markers in monitoring percutaneous coronary interventions with frequent use of stents and gpIIbIIIa-antagonists.
    Mark B; Schneider S; Schiele R; Taubert G; Kilkowski C; Seidl K; Nagel D; Seiler D; Senges J; Zahn R
    Z Kardiol; 2003 Dec; 92(12):1018-24. PubMed ID: 14663612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
    Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
    Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Naproxen treatment prevents periprocedural inflammatory response but not myocardial injury after percutaneous coronary intervention.
    Ozdol C; Gulec S; Rahimov U; Atmaca Y; Turhan S; Erol C
    Thromb Res; 2007; 119(4):453-9. PubMed ID: 17157900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of periprocedural creatine kinase-MB isoenzyme release on long-term mortality in contemporary percutaneous coronary intervention.
    Andron M; Stables RH; Egred M; Alahmar AE; Shaw MA; Roberts E; Albouaini K; Grayson AD; Perry RA; Palmer ND
    J Invasive Cardiol; 2008 Mar; 20(3):108-12. PubMed ID: 18316825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.
    Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W
    EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome.
    Perez de Prado A; Cuellas C; Diego A; de Miguel A; Samaniego B; Alonso-Orcajo N; Carbonell R; Pascual C; Fernandez-Vazquez F; Calabozo RG
    Thromb Res; 2009 Dec; 124(6):678-82. PubMed ID: 19411094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation.
    Siller-Matula JM; Haberl K; Prillinger K; Panzer S; Lang I; Jilma B
    Thromb Res; 2009 Apr; 123(6):874-80. PubMed ID: 19135705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
    Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
    J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term prognostic value of cardiac troponin I and T versus creatine kinase-MB mass after cardiac surgery in low-risk patients with stable symptoms.
    Vikenes K; Andersen KS; Melberg T; Farstad M; Nordrehaug JE
    Am J Cardiol; 2010 Sep; 106(6):780-6. PubMed ID: 20816117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention.
    Mangiacapra F; Patti G; Peace A; Gatto L; Vizzi V; Ricottini E; D'Ambrosio A; Muller O; Barbato E; Di Sciascio G
    Am J Cardiol; 2010 Sep; 106(5):619-23. PubMed ID: 20723634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.
    Hochholzer W; Trenk D; Bestehorn HP; Fischer B; Valina CM; Ferenc M; Gick M; Caputo A; Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2006 Nov; 48(9):1742-50. PubMed ID: 17084243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention.
    Quinn MJ; Bhatt DL; Zidar F; Vivekananthan D; Chew DP; Ellis SG; Plow E; Topol EJ
    Am J Cardiol; 2004 Mar; 93(6):679-84. PubMed ID: 15019868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention.
    Price MJ; Nayak KR; Barker CM; Kandzari DE; Teirstein PS
    Am J Cardiol; 2009 May; 103(10):1339-43. PubMed ID: 19427425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
    Lewis BS; Mehta SR; Fox KA; Halon DA; Zhao F; Peters RJ; Keltai M; Budaj A; Yusuf S;
    Am Heart J; 2005 Dec; 150(6):1177-84. PubMed ID: 16338255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes.
    Karha J; Gurm HS; Rajagopal V; Fathi R; Bavry AA; Brener SJ; Lincoff AM; Ellis SG; Bhatt DL
    Am J Cardiol; 2006 Oct; 98(7):906-10. PubMed ID: 16996871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postprocedural hyperglycemia in ST elevation myocardial infarction submitted to percutaneous coronary intervention: a prognostic indicator and a marker of metabolic derangement.
    Lazzeri C; Chiostri M; Sori A; Valente S; Gensini GF
    J Cardiovasc Med (Hagerstown); 2010 Jan; 11(1):7-13. PubMed ID: 19829142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.